Table 2.
Dsg2 expression level and CC patients’ clinicopathological characteristics
| Characteristics | n | Dsg2 | Pearson X2 | P-value | |
|---|---|---|---|---|---|
| Low and no | High | ||||
| Total | 587 | 330 (56.22%) | 257 (43.78%) | ||
| Gender | 0.54 | 0.463 | |||
| Male | 351 | 193 (54.99%) | 158 (45.01%) | ||
| Female | 236 | 137 (58.05%) | 99 (41.95%) | ||
| Age | 0.79 | 0.376 | |||
| < 60 | 215 | 126 (58.60%) | 89 (41.40%) | ||
| ≥ 60 | 372 | 204 (54.84%) | 168 (45.16%) | ||
| Location | 3.02 | 0.389 | |||
| Right | 188 | 110 (58.51%) | 78 (41.49%) | ||
| Transverse | 77 | 46 (59.74%) | 31 (40.26%) | ||
| Left | 114 | 67 (58.77%) | 47 (41.23%) | ||
| Sigmoid | 208 | 107 (51.44%) | 101 (48.56%) | ||
| Histological type | 0.42 | 0.515 | |||
| Adenocarcinoma | 522 | 291 (55.75%) | 231 (44.25%) | ||
| Mucinous/SRCCa | 65 | 39 (60.00%) | 26 (40.00%) | ||
| Differentiation | 8.77 | 0.033* | |||
| Well | 156 | 83 (53.21%) | 73 (46.95%) | ||
| Moderate | 314 | 173 (55.10%) | 141 (44.91%) | ||
| Poor | 99 | 58 (58.59%) | 41 (41.41%) | ||
| Othersb | 18 | 16 (88.89%) | 2 (11.11%) | ||
| Tumor size | 1.44 | 0.696 | |||
| T1 | 42 | 25 (59.52%) | 17 (40.48%) | ||
| T2 | 61 | 37 (60.66%) | 24 (39.34%) | ||
| T3 | 200 | 115 (57.50%) | 85 (42.50%) | ||
| T4 | 284 | 153 (53.87%) | 131 (46.13%) | ||
| Lymph node metastasis | 6.21 | 0.045* | |||
| N0 | 328 | 171 (52.13%) | 157 (47.87%) | ||
| N1 | 168 | 99 (58.93%) | 69 (41.07%) | ||
| N2 | 91 | 60 (65.93%) | 31 (34.07%) | ||
| Distant metastasis | 7.90 | 0.005* | |||
| M0 | 495 | 266 (53.74%) | 229 (46.26%) | ||
| M1 | 92 | 64 (69.57%) | 28 (30.43%) | ||
| AJCC stage | 18.54 | < 0.001* | |||
| I | 63 | 28 (44.44%) | 35 (55.56%) | ||
| II | 199 | 95 (47.74%) | 104 (52.26%) | ||
| III | 233 | 143 (61.37%) | 90 (38.63%) | ||
| IV | 92 | 64 (69.57%) | 28 (30.43%) | ||
| Venous invasion | 0.15 | 0.697 | |||
| Negative | 501 | 280 (55.89%) | 221 (44.11%) | ||
| Positive | 86 | 50 (58.14%) | 36 (41.86%) | ||
| Perineural invasion | 0.24 | 0.623 | |||
| Negative | 507 | 283 (55.82%) | 224 (44.18%) | ||
| Positive | 80 | 47 (58.75%) | 33 (41.25%) | ||
| Preoperative CEA, ng/ml | 1.17 | 0.557 | |||
| ≤ 5 | 259 | 150 (57.92%) | 109 (42.08%) | ||
| > 5 | 285 | 154 (54.04%) | 131 (45.96%) | ||
| Unknown | 43 | 26 (60.47%) | 17 (39.53%) | ||
| Preoperative CA199, ng/ml | 1.06 | 0.588 | |||
| ≤ 37 | 261 | 151 (57.85%) | 110 (42.15%) | ||
| > 37 | 281 | 152 (54.09%) | 129 (45.91%) | ||
| Unknown | 45 | 27 (60.00%) | 18 (40.00%) | ||
| Ki67 | 0.58 | 0.444 | |||
| Negative | 181 | 106 (58.56%) | 75 (41.44%) | ||
| Positive | 406 | 224 (55.17%) | 182 (44.83%) | ||
*P < 0.05 indicated a significant associated with clinical characteristics
aMucinous carcinoma is 57 cases; SRCC (signet-ring cell carcinoma) is 8 cases
bNo clear differentiation stage diagnosis